ImmuPharma (LON:IMM) Trading Up 34.1% - Here's What Happened

Key Points

• ImmuPharma plc's stock experienced a significant rise of 34.1% during mid-day trading, reaching a high of GBX 11.50 ($0.16).
• The trading volume surged to approximately 57.6 million shares, marking a 656% increase compared to its average daily volume.
• ImmuPharma reported a negative earnings per share (EPS) of GBX (0.38) for the previous quarter and analysts predict it will post a current year EPS of -339.0000022.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price rose 34.1% during mid-day trading on Tuesday . The stock traded as high as GBX 11.50 ($0.16) and last traded at GBX 10.81 ($0.15). Approximately 57,593,953 shares were traded during mid-day trading, an increase of 656% from the average daily volume of 7,620,919 shares. The stock had previously closed at GBX 8.06 ($0.11).

ImmuPharma Price Performance

The business's 50 day simple moving average is GBX 2.55 and its 200 day simple moving average is GBX 2.76. The stock has a market cap of £54.02 million, a P/E ratio of -1,214.61 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Research analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.